Pharmacological Induction of RAS-GTP Confers RAF Inhibitor Sensitivity in KRAS Mutant Tumors

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• Targeting KRAS mutant tumors via single downstream pathway inhibition has yielded limited clinical success.
• RAF inhibitors show minimal efficacy in KRAS mutant tumors.
• Understanding resistance mechanisms is crucial for effective cancer therapy.

Purpose of the Study:

• To investigate synergistic drug combinations for targeting KRAS mutant tumors.
• To elucidate the mechanism underlying the synergy between RAF, MEK, and PI3K inhibitors.
• To identify predictive biomarkers for response to combination therapy.

Main Methods:

• Utilized combination drug screening in a broad panel of cancer cell lines.
• Performed mechanistic studies involving RAS-GTP level assessment, RAF dimerization assays, and kinase activity measurements.
• Analyzed synergistic efficacy across different KRAS mutation subtypes (e.g., KRASG13D vs. KRASG12).

Main Results:

• MEK and PI3K inhibitors synergized with pan-RAF inhibitors via an RAS-GTP-dependent mechanism.
• RAF/MEK inhibitor combinations demonstrated synergistic efficacy in both KRAS mutant and wild-type tumors.
• KRASG13D mutant tumors exhibited greater synergy compared to KRASG12 mutant tumors.
• MEK inhibition was shown to induce RAS-GTP levels, RAF dimerization, and RAF kinase activity, leading to MEK phosphorylation.

Conclusions:

• Combination therapy involving MEK and PI3K inhibitors with pan-RAF inhibitors offers a viable strategy for KRAS mutant tumors.
• This approach can rewire tumors to overcome resistance and confer sensitivity to RAF kinase inhibition.
• The findings suggest a potential therapeutic window for combination therapies irrespective of KRAS mutational status.